ProQR Therapeutics N.V. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2024 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2024 | 3 | -$0.13 | -$0.08 | -$0.11 |
| Q4 2024 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q1 2025 | 2 | -$0.08 | -$0.08 | -$0.08 |
| Q2 2025 | 2 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2025 | 2 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2025 | 2 | -$0.13 | -$0.13 | -$0.13 |
ProQR Therapeutics N.V. Earnings Date And Information
ProQR Therapeutics N.V. last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.03 earnings per share for the quarter, topping analysts' consensus estimates of $-0.12 by $0.09. The company had revenue of 6.34 M for the quarter and had revenue of 6.38 M for the year. ProQR Therapeutics N.V. has generated $0 earnings per share over the last year ($-0.34 diluted earnings per share) and currently has a price-to-earnings ratio of -12.77. ProQR Therapeutics N.V. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
ProQR Therapeutics N.V. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/08/2024 | Q2 2024 | -$0.12 | -$0.03 | 0.09 | $11.44 M | $6.34 M |
| 05/09/2024 | Q1 2024 | -$0.12 | -$0.09 | 0.03 | $4.48 M | |
| 03/13/2024 | Q4 2023 | -$0.08 | -$0.07 | 0.01 | $3.20 M | |
| 11/07/2023 | Q3 2023 | -$0.06 | -$0.07 | -0.01 | $4.64 M | $1.37 M |
| 08/03/2023 | Q2 2023 | -$0.12 | -$0.10 | 0.02 | $1.22 M | $1.21 M |
| 05/16/2023 | Q1 2023 | -$0.12 | -$0.10 | 0.02 | $655,000 | |
| 03/29/2023 | Q4 2022 | -$0.20 | -$0.14 | 0.06 | $822,000 | |
| 11/09/2022 | Q3 2022 | -$0.23 | -$0.34 | -0.11 | $841,846 | $956,000 |
| 05/05/2022 | Q2 2022 | -$0.25 | -$0.21 | 0.04 | $865,203 | $1.03 M |
| 05/05/2022 | Q1 2022 | -$0.25 | -$0.20 | 0.05 | $1.23 M | |
| 04/29/2022 | Q4 2021 | -$0.26 | $239,000 | |||
| 11/04/2021 | Q3 2021 | -$0.23 | -$0.22 | 0.01 | $234,520 | $872,000 |
| 05/06/2021 | Q2 2021 | -$0.28 | -$0.24 | 0.04 | $191,668 | $243,000 |
| 05/06/2021 | Q1 2021 | -$0.28 | -$0.25 | 0.03 | $0 | |
| 03/24/2021 | Q4 2020 | -$0.26 | $0 | |||
| 11/16/2020 | Q3 2020 | -$0.27 | -$0.26 | 0.01 | $99,836 | $0 |
| 05/07/2020 | Q2 2020 | -$0.46 | -$0.08 | 0.38 | $318,308 | $0 |
| 05/07/2020 | Q1 2020 | -$0.46 | -$0.32 | 0.14 | $0 | |
| 03/31/2020 | Q4 2019 | -$0.39 | $1.93 M | |||
| 02/26/2020 | Q3 2019 | -$0.48 | -$0.31 | 0.17 | $863,952 | $0 |
ProQR Therapeutics N.V. Earnings: Frequently Asked Questions
-
When is ProQR Therapeutics N.V.'s earnings date?
ProQR Therapeutics N.V. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did ProQR Therapeutics N.V. beat their earnings estimates last quarter?
In the previous quarter, ProQR Therapeutics N.V. (:PRQR) reported $-0.03 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.12 by $0.09.
-
How can I listen to ProQR Therapeutics N.V.'s earnings conference call?
The conference call for ProQR Therapeutics N.V.'s latest earnings report can be listened to online.
-
How can I read ProQR Therapeutics N.V.'s conference call transcript?
The conference call transcript for ProQR Therapeutics N.V.'s latest earnings report can be read online.
-
How much revenue does ProQR Therapeutics N.V. generate each year?
ProQR Therapeutics N.V. (:PRQR) has a recorded annual revenue of $6.38 M.
-
How much profit does ProQR Therapeutics N.V. generate each year?
ProQR Therapeutics N.V. (:PRQR) has a recorded net income of $6.38 M. ProQR Therapeutics N.V. has generated $-0.34 earnings per share over the last four quarters.
-
What is ProQR Therapeutics N.V.'s price-to-earnings ratio?
ProQR Therapeutics N.V. (:PRQR) has a price-to-earnings ratio of -12.77 and price/earnings-to-growth ratio is -0.7.
